{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:11Z","timestamp":1786119191206,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1097\/rlu.0b013e31815976a5","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T20:39:53Z","timestamp":1236199193000},"page":"952-953","source":"Crossref","is-referenced-by-count":3,"title":["In-111 Ibritumomab Scintigraphy (Planar and SPECT) and FDG PET\/CT Before Y-90 Ibritumomab Treatment in a Patient With Mantle Cell Lymphoma"],"prefix":"10.1097","volume":"32","author":[{"given":"Julio Francisco","family":"Jim\u00e9nez-Bonilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remedios","family":"Quirce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Banzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Mart\u00ednez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Sainz-Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Enrique","family":"Barrag\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"L\u00f3pez-Cordovilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Carril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210204","first-page":"1507","article-title":"Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.","volume":"43","author":"Juweid","year":"2002","journal-title":"J Nucl Med"},{"key":"R2-13-20210204","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low grade, follicular or transformed B-cell non-Hodgkin's lymphoma.","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"R3-13-20210204","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1157\/13083351","article-title":"Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status.","volume":"25","author":"Emmanouilides","year":"2006","journal-title":"Rev Esp Med Nucl"},{"key":"R4-13-20210204","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1007\/s00259-006-0132-4","article-title":"Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas.","volume":"33","author":"Mikhaeel","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-13-20210204","first-page":"1812","article-title":"The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a zevalin imaging registry.","volume":"46","author":"Conti","year":"2005","journal-title":"J Nucl Med"},{"key":"R6-13-20210204","first-page":"267","article-title":"Administration Guidelines for Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody.","volume":"43","author":"Wagner","year":"2002","journal-title":"J Nucl Med"},{"issue":"1, suppl 1","key":"R7-13-20210204","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.semnuclmed.2003.11.004","article-title":"Imaging and dosing radioimmunotherapy with yttrium 90-ibritumomab tiuxetan (Zevalin).","volume":"34","author":"Spies","year":"2004","journal-title":"Semin Nucl Med"},{"key":"R8-13-20210204","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s00259-007-0372-y","article-title":"EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90-Y-radiolabelled ibritumomab tiuxetan (Zevalin).","volume":"34","author":"Tennvall","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R9-13-20210204","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1157\/13083353","article-title":"Radioimmunotherapy with 90-Y-ibritumomab tiuxetan in lymphomas.","volume":"25","author":"Setoain","year":"2006","journal-title":"Rev Esp Med Nucl"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003072-200712000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:42:30Z","timestamp":1786038150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003072-200712000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0b013e31815976a5","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}